One company that is starting to gain recognition on Wall Street is Cord Blood America. Located in Las Vegas, Nevada, Cord Blood is the parent company of CorCell which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Cord Blood is at the forefront of the healthcare sector and offers powerful and potential life-saving resources for treating a growing number of ailments which include cancer, leukemia, blood, and immune disorders.
Cord Blood’s leader Matthew Schissler, the co-founder and CEO of the growing corporation, agreed to an analyst interview recently and discussed increasing the company’s revenues. In the interview with analyst Francis Gaskins, Schissler stated that the focus for Cord Blood this year is top-line revenue growth. Schissler went on to highlight a number of reasons why Cord Blood is starting to gain recognition in the market place.
One of the main reasons Cord Blood is making waves in their field is the announcement that it is seeking to purchase controlling interest in a rising South American stem cell company. If this purchase is completed, Cord Blood could see an increase in revenue by $1.0 to $1.5 million in the next 12 month time frame.
Another reason revenues are looking up at Cord Blood is the purchase of a stem cell company in Germany. The company could add up to $1 million in revenues in the next year with this venture.
Cord Blood America recently went on a visit to China where its new facility will provide storage of 10 times the size of the company’s new Las Vegas laboratory which is believed to be the largest of its kind in U.S. – Operations are scheduled to begin in 2011.
Cord Blood has constantly provided hope and results to investors and has truly established a global presence. Currently, Cord Blood is trading in the $0.0097 range. With all of the highlights discussed by Matthew Schissler and even more in the company pipeline, Cord Blood could potentially become a dynamic force within the stem cell industry.
Let us hear your thoughts below: